Home Current Issue Previous Issues Published Ahead-of-Print Collections CE For Authors Journal Info
Editor-in-Chief: V.Susan Carroll, MS, RN-BC
ISSN: 0888-0395
Online ISSN: 1945-2810
Frequency: 6 issues per year
Impact Factor: .756
From the Editor
Congratulations to the JNN Writing Award winners ... Amy Hester for her article "Validation of the Hester Davis Scale for Fall Risk Assessment in a Neurosciences Population" (October, 2013) an Cathy Cartwright for her article "Mock Herniations to Assess Nurses' Response Times and Accuracy in Setting Up Ventriculostomies in the Pediatric Intensive Care Unit" (February, 2013. Take time to read both of these great articles that support best practice and nurse education. JNN will soon add a number of publishing standards to our Editorial Manager website that provide guidance for authors as they submit systematic reviews of the literature, observational studies, qualitative research, and randomized research studies. Guidelines for ethical publishing will also be posted here.
Featured Supplement

JNN December 2013 Supplement
 

This supplement was developed with the support of Genzyme, a Sanofi company.

 

Current Issue Highlights

Actions
View
Actions
View
Login

American Association of Neuroscience Nurses Official Journal of
American Association of Neuroscience Nurses

To receive access to the online journal, association members must log-in through the AANN website in the members-only area. Please click below:

American Association of Neuroscience Nurses

In the News
A recent article in Stroke reported that only slightly more than 50% of women surveyed were unable to identify more than one sign of a stroke. The vast majority did, however, report that calling 911 was essential to treatment. Because stroke remains the 3rd leading cause of death among women in the US, this highlights a gap in health education that is ominous. It appears to be increasingly possible to predict the development of Alzheimer disease using blood biomarkers. Researchers at Georgetown University evaluated the levels of 10 plasma phospholipid molecules as a means of identifying healthy individuals who later developed cognitive impairments. This work holds promise as a predictive test and as part of future clinical trials. In mid-March the FDA approved a headband that delivers electrical nerve stimulation to prevent migraine onset. The device is worn around the head with a TENS stimulator centered on the forehead just above the eyes, sending a small current to the branches of the trigeminal nerve.